ArticleTherapeutic advances in respiratory disease

Combination therapy of gefitinib and miR-30a-5p may overcome acquired drug resistance through regulating the PI3K/AKT pathway in non-small cell lung cancer.

Fengfeng Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.